U
GALT icon

UBS’s Galectin Therapeutics GALT Stock Holding History

UBS’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$22K Buy
4,377
+1,452
+50% +$11.3K ﹤0.01% 7877
2014
Q2 		$40K Sell
2,925
-54,983
-95% -$684K ﹤0.01% 7160
2014
Q1 		$887K Buy
57,908
+55,581
+2,389% +$791K ﹤0.01% 3606
2013
Q4 		$18K Buy
2,327
+629
+37% +$5.81K ﹤0.01% 8271
2013
Q3 		$17K Buy
1,698
+1,281
+307% +$8.64K ﹤0.01% 8248
2013
Q2 		$2K Buy
+417
New +$1.71K ﹤0.01% 9781

Other funds holding GALT

CCA
Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

UBS's GALT Position: Q3 2014 in Review

UBS increased its Galectin Therapeutics (GALT) stake by 50% in Q3 2014, buying an estimated $11.3K and bringing the position to 4,377 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #7877.

UBS first reported a position in GALT in Q2 2013 and has held it in 6 quarters since. The position peaked at $887K in Q1 2014. 63 funds tracked by Wall St. Rank hold GALT as of Q3 2014.

  • UBS held 4,377 shares of Galectin Therapeutics worth $22K as of Q3 2014.
  • UBS bought 1,452 Galectin Therapeutics shares in Q3 2014, an estimated $11.3K.
  • Galectin Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7877 holding.
  • UBS first reported a position in Galectin Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Galectin Therapeutics position peaked at $887K in Q1 2014.
  • 63 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.